Explore

Trendline Trendline
Braveheart Bio Develops New Therapies for Cardiovascular Diseases

Braveheart Bio Develops New Therapies for Cardiovascular Diseases

Braveheart Bio Develops New Therapies for Cardiovascular Diseases
Trendline Trendline
Atossa Therapeutics Advances Breast Cancer Treatment with Phase 2 Drug Development

Atossa Therapeutics Advances Breast Cancer Treatment with Phase 2 Drug Development

Atossa Therapeutics Advances Breast Cancer Treatment with Phase 2 Drug Development
Trendline Trendline
GLP-1 Drugs: A Catalyst for Growth in Digital Health Platforms

GLP-1 Drugs: A Catalyst for Growth in Digital Health Platforms

GLP-1 Drugs: A Catalyst for Growth in Digital Health Platforms
Trendline Trendline
Soligenix Reports Financial Results and Strategic Updates Amidst Program Discontinuation

Soligenix Reports Financial Results and Strategic Updates Amidst Program Discontinuation

Soligenix Reports Financial Results and Strategic Updates Amidst Program Discontinuation
Trendline Trendline
Northwest Biotherapeutics and SPIMACO Sign MOU for Cancer Therapy Collaboration

Northwest Biotherapeutics and SPIMACO Sign MOU for Cancer Therapy Collaboration

Northwest Biotherapeutics and SPIMACO Sign MOU for Cancer Therapy Collaboration
Trendline Trendline
Nielsen to Acquire DoubleVerify for $2.15 Billion in Strategic Expansion

Nielsen to Acquire DoubleVerify for $2.15 Billion in Strategic Expansion

Nielsen to Acquire DoubleVerify for $2.15 Billion in Strategic Expansion
Trendline Trendline
USA Today Co. Partners with Palantir for Data Monetization

USA Today Co. Partners with Palantir for Data Monetization

USA Today Co. Partners with Palantir for Data Monetization
Trendline Trendline
Meduloc Secures $4 Million Series B Funding to Advance Orthopedic Innovations

Meduloc Secures $4 Million Series B Funding to Advance Orthopedic Innovations

Meduloc Secures $4 Million Series B Funding to Advance Orthopedic Innovations
Trendline Trendline
Palantir's Tax Practices Under Scrutiny Amid Controversial Government Contracts

Palantir's Tax Practices Under Scrutiny Amid Controversial Government Contracts

Palantir's Tax Practices Under Scrutiny Amid Controversial Government Contracts
Trendline Trendline
Biohaven Appoints John Yetimoglu to Board to Enhance AI-Driven Drug Development

Biohaven Appoints John Yetimoglu to Board to Enhance AI-Driven Drug Development

Biohaven Appoints John Yetimoglu to Board to Enhance AI-Driven Drug Development
Trendline Trendline
Peter Thiel Maintains Significant Stake in Palantir, Signaling Confidence in Company's Growth

Peter Thiel Maintains Significant Stake in Palantir, Signaling Confidence in Company's Growth

Peter Thiel Maintains Significant Stake in Palantir, Signaling Confidence in Company's Growth
Trendline Trendline
Initiate Government Solutions Seeks AI/ML Engineer for Federal Healthcare Projects

Initiate Government Solutions Seeks AI/ML Engineer for Federal Healthcare Projects

Initiate Government Solutions Seeks AI/ML Engineer for Federal Healthcare Projects